Accelerating Global Expansion
First written in FY2016. 29 of 38 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-07-30.
The whole theme swung hardest in 2017: 1 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Overseas revenue continued to increase, driven by higher sales of fecal occult blood testing reagents and medical equipment, reaching ¥11,457 million, up 7.0% year on year.」
Overseas sales rose 7.0% year on year to ¥11,457 million, driven by growth in fecal occult blood testing reagents and medical devices. Next fiscal year, overseas sales are expected to reach ¥11,790 million, up 2.9%, accounting for 28.0% of revenue. - FY2026-H1AdvancedAnnual report
「Overseas sales were ¥5,449 million, up 11.3% year on year.」
Overseas sales rose 11.3% year on year to ¥5,449 million, reflecting progress in overseas expansion. - FY2025AdvancedAnnual report
「In overseas markets, testing demand is expected to expand substantially, driven by an increase in the number of countries adopting our fecal occult blood testing reagents, which are driving our growth, as well as the expansion of the eligible age range for colorectal cancer screening in various countries. For the next fiscal year, we forecast revenue of ¥42,200 million, up 4.1% year on year, reflecting higher overseas sales of fecal occult blood testing reagents and Mycobacterium tuberculosis complex detection reagent kits. Overseas sales are expected to be ¥12,050 million, up 12.5%, accounting for 28.6% of revenue.」
Overseas sales recovered to ¥10,710 million, up 5.9% year on year, and are expected to reach ¥12,050 million, up 12.5%, in the next fiscal year, giving concrete form to the expansion of overseas operations. - FY2025-H1Decline in overseas salesAnnual report
「Overseas sales were ¥4,898 million, up strongly on sales of urinalysis reagents but down 6.4% year on year due to lower sales of fecal occult blood testing reagents.」
Overseas sales fell 6.4% year on year as the decline in fecal occult blood testing reagents offset growth in urinalysis reagents. - FY2024-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥7,696 million, up 16.8% year on year.」
Overseas revenue was ¥7,696 million, up 16.8% year on year, indicating growth in the company's global expansion, led by fecal occult blood testing reagents. - FY2024-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥5,233 million, up 18.6% year on year.」
Overseas revenue from fecal occult blood testing reagents was ¥5,233 million, up 18.6% year on year, indicating growth in the company's global expansion. - FY2024-Q1AdvancedAnnual report
「Overseas revenue increased as sales of fecal occult blood testing reagents rose following the resolution of the impact of inventory adjustments, despite a decline in sales of urinalysis reagents, reaching ¥2,523 million, up 12.3% year on year.」
The impact of inventory adjustments was resolved, and overseas revenue recovered, increasing 12.3% year on year, led by fecal occult blood testing reagents. - FY2023-Q3Decline in overseas sales due to inventory adjustmentsAnnual report
「Overseas revenue increased for urinalysis reagents, but sales of fecal occult blood testing reagents declined because inventories were increased in preparation for the resumption of screening programs and subsequently adjusted, resulting in revenue of ¥6,587 million, down 1.1% year on year.」
In overseas markets, sales of urinalysis reagents increased, while sales of fecal occult blood testing reagents declined because inventories were built up before the resumption of screening programs and subsequently adjusted, resulting in a 1.1% year-on-year decline in overseas revenue. - FY2023-Q2RestatedAnnual report
「Overseas revenue increased for urinalysis reagents, but sales of fecal occult blood testing reagents declined, resulting in revenue of ¥4,412 million, down 4.9% year on year.」
In overseas markets, sales of urinalysis reagents increased, while the decline in fecal occult blood testing reagents resulted in a 4.9% year-on-year decrease in overseas revenue. - FY2023-Q1Decline in overseas salesAnnual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined, resulting in revenue of ¥2,246 million, down 4.0% year on year.」
Sales of urinalysis products increased, while lower sales of fecal occult blood testing products resulted in a 4.0% year-on-year decline in overseas revenue. - FY2022AdvancedAnnual report
「In addition, overseas revenue increased on growth in sales of fecal occult blood testing reagents and analyzers following the resumption of national screening programs, reaching ¥8,868 million, up 28.6% year on year.」
Against the backdrop of the resumption of national screening programs, overseas revenue was ¥8,868 million, up 28.6% year on year. - FY2022-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers following the resumption of national screening programs, reaching ¥6,660 million, up 41.3% year on year.」
Against the backdrop of the resumption of national screening programs, overseas revenue from fecal occult blood testing reagents and analyzers was ¥6,660 million, up 41.3% year on year. - FY2022-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers following the resumption of national screening programs, reaching ¥4,637 million, up 60.1% year on year.」
Against the backdrop of the resumption of national screening programs, overseas revenue from fecal occult blood testing reagents and analyzers increased 60.1% year on year, further advancing the company's overseas expansion. - FY2022-Q1AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers, reaching ¥2,339 million, up 46.5% year on year.」
Overseas revenue from fecal occult blood testing reagents and analyzers increased 46.5% year on year, marking progress in overseas expansion. - FY2021AdvancedAnnual report
「As colorectal cancer screening programs that had been suspended because of the spread of COVID-19 resumed in various countries and demand began to recover, we renewed our contract for Australia's national colorectal cancer screening program.」
The resumption of national screening programs and the trend toward recovering demand were evident, and the contract for Australia's national screening program was renewed. - FY2021-Q3Slower overseas expansion due to the COVID-19 pandemicAnnual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined as participation in national screening programs decreased or programs were suspended, resulting in revenue of ¥4,712 million, down 10.1% year on year.」
Sales of urinalysis products increased, while fecal occult blood products declined because of lower participation in or suspension of national screening programs, resulting in a 10.1% year-on-year decline in overseas revenue. - FY2021-Q2Slower overseas expansion due to the COVID-19 pandemicAnnual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined as participation in national screening programs decreased or programs were suspended, resulting in revenue of ¥2,897 million, down 17.7% year on year.」
In overseas markets, sales of urinalysis products increased, while sales of fecal occult blood products declined because of lower participation in or suspension of national screening programs, resulting in a 17.7% year-on-year decline in overseas revenue. - FY2020AdvancedAnnual report
「We focused on expanding adoption of fecal occult blood testing reagents and analyzers in the United States and pursued activities aimed at winning national colorectal cancer screening programs, mainly in Europe and the Middle East. In France, continued adoption of the national screening program was approved. For urinalysis reagents and analyzers for overseas markets, we worked to expand sales through cooperation with SYSMEX CORPORATION, contributing to the increase in overseas revenue.」
Continued adoption of France's national colorectal cancer screening program was approved, and expanded sales of overseas urinalysis products through cooperation with SYSMEX CORPORATION contributed to higher overseas revenue. - FY2020-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥5,242 million, up 24.6% year on year.」
Overseas revenue from fecal occult blood testing reagents and urinalysis reagents and analyzers was ¥5,242 million, up 24.6% year on year, marking progress in overseas expansion. - FY2020-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥3,520 million, up 31.1% year on year.」
Overseas revenue from fecal occult blood testing reagents and urinalysis reagents and analyzers was ¥3,520 million, up 31.1% year on year. - FY2020-Q1AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥1,803 million, up 35.1% year on year.」
Overseas revenue from fecal occult blood testing reagents and urinalysis reagents and analyzers increased 35.1% year on year, marking progress in overseas expansion. - FY2019AdvancedAnnual report
「We focused on expanding adoption of fecal occult blood testing reagents and analyzers in the United States and continued activities aimed at winning national colorectal cancer screening programs, mainly in Europe and the Middle East. For urinalysis reagents and analyzers for overseas markets, we promoted cooperation with SYSMEX CORPORATION and worked to expand sales. In genetic testing, we promoted clinical trials, mainly in Asia and Africa, in preparation for the global rollout of LAMP-based genetic testing reagents for the Mycobacterium tuberculosis complex and malaria. Based on the adoption case in Cameroon, we are working to replicate the model in other countries.」
The document describes activities in the United States, Europe and the Middle East, cooperation with SYSMEX CORPORATION, clinical trials in Asia and Africa, and expansion into other countries based on the adoption case in Cameroon. - FY2019-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥4,208 million, up 9.6% year on year.」
Overseas revenue from fecal occult blood testing reagents was ¥4,208 million, up 9.6% year on year, marking progress in overseas expansion. - FY2019-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥2,685 million, up 9.0% year on year.」
Overseas revenue from fecal occult blood testing reagents was ¥2,685 million, up 9.0% year on year, marking progress in overseas expansion. - FY2019-Q1AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers, reaching ¥1,335 million, up 12.6% year on year.」
Overseas revenue from fecal occult blood testing reagents and analyzers increased 12.6% year on year, marking progress in overseas expansion. - FY2018RestatedAnnual report
「We focused on expanding adoption of fecal occult blood testing reagents and analyzers in the United States, continued activities aimed at winning national colorectal cancer screening programs, mainly in Europe and the Middle East, and won a national screening program in Australia in Oceania.」
The company continued activities in the United States, Europe and the Middle East and reiterated its record of winning a national screening program in Australia. - FY2018-Q3AdvancedAnnual report
「We focused on expanding adoption of fecal occult blood testing reagents and analyzers in the United States, continued activities aimed at winning national colorectal cancer screening programs, mainly in Europe and the Middle East, and won a national screening program in Australia in Oceania. We also promoted Field Studies, mainly in Africa and Asia, in preparation for the global rollout of LAMP-based tuberculosis and malaria genetic testing reagents. In addition, the TB-LAMP tuberculosis genetic testing product was included in the GDF (Global Drug Facility*) catalog. (*The Global Drug Facility is an important program of the Stop TB Partnership that enables countries to obtain high-quality medicines and diagnostic tools at affordable prices.)」
In addition to the company's existing expansion activities in the United States, Europe, the Middle East and Australia and its Field Studies, the TB-LAMP product was included in the GDF catalog. - FY2018-Q2AdvancedAnnual report
「We focused on expanding adoption of fecal occult blood testing reagents and analyzers in the United States, continued activities aimed at winning national colorectal cancer screening programs, mainly in Europe and the Middle East, and won a national screening program in Australia in Oceania. We also promoted Field Studies, mainly in Africa and Asia, in preparation for the global rollout of LAMP-based tuberculosis and malaria genetic testing reagents.」
We continued activities in the United States, Europe and the Middle East and won a national screening program in Australia. We also promoted Field Studies for LAMP-based products in Africa and Asia. - FY2018-Q1AdvancedAnnual report
「We focused on expanding adoption of fecal occult blood testing reagents and analyzers in the United States, while continuing activities aimed at winning national colorectal cancer screening programs, mainly in Europe and the Middle East. We also promoted Field Studies, mainly in Africa and Asia, in preparation for the global rollout of LAMP-based tuberculosis and malaria genetic testing reagents.」
In addition to ongoing overseas expansion activities in the United States, Europe and the Middle East, the company promoted Field Studies for tuberculosis and malaria genetic testing reagents in Africa and Asia. - FY2017AdvancedAnnual report
「Following the issuance of new guidelines for colorectal cancer screening in the United States in June 2016, we focused on expanding adoption of fecal occult blood testing reagents and analyzers. We also continued activities aimed at winning national colorectal cancer screening programs in countries across Europe and won a national screening program in Qatar in the Middle East. The tuberculosis genetic testing method using LAMP that we had been co-developing with FIND (Foundation for Innovative New Diagnostics) received a WHO recommendation, and POLICY GUIDANCE was issued. We also entered into a global sales agreement with Germany's HUMAN Gesellschaft fuer Biochemica und Diagnostica mbH for tuberculosis and malaria genetic testing reagents and began sales. In February 2017, our proposed project to promote the adoption of population-based colorectal cancer screening in Thailand was selected under JICA's Private Sector Partnership Program for Disseminating Japanese Technologies.」
In addition to winning a national screening program in Qatar, the company began sales under its agreement with HUMAN, and its Thailand project was selected for a JICA program, adding specific progress in overseas expansion. - FY2017-Q3AdvancedAnnual report
「Following the issuance of new guidelines for colorectal cancer screening in the United States in June 2016, we focused on expanding adoption of fecal occult blood testing reagents and analyzers. We also continued activities aimed at winning national colorectal cancer screening programs in countries across Europe and won a national screening program in Qatar in the Middle East.」
We continued activities to expand adoption in the United States and Europe and won a national screening program in Qatar. - FY2017-Q2AdvancedAnnual report
「Following the issuance of new guidelines for colorectal cancer screening in the United States in June 2016, we focused on expanding adoption of fecal occult blood testing reagents and analyzers. In Europe, we continued activities aimed at winning national colorectal cancer screening programs in Germany and England.」
In the United States, we pursued activities to expand adoption in response to the new guidelines, while in Europe we continued activities aimed at winning national screening programs in Germany and England. - FY2017-Q1RestatedAnnual report
「We focused on expanding adoption of fecal occult blood testing reagents and analyzers in the United States, while continuing activities aimed at winning national colorectal cancer screening programs in Europe, including England.」
We continue to pursue global expansion by expanding adoption in the United States and winning national screening programs in Europe. - FY2016First statedAnnual report
「Accelerating global expansion」
The priority issues include expanding fecal occult blood testing reagents and analyzers in North America and Asia, and urinalysis reagents and analyzers in Italy.